OncoMatch/Clinical Trials/NCT06801002
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Is NCT06801002 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JBZ-001 for solid tumor.
Treatment: JBZ-001 — This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001, a DHODH inhibitor, in patients with refractory solid and hematological malignancies. The study design includes two independent parts: dose escalation in solid tumors and NHL (Part 1), and up to four indication expansions in selected solid tumor types and NHL (Part 2). The dose escalation will enroll patients with solid tumors and NHL following a standard "3+3" design enrolling a minimum of 3 and up to 6 patients per dose level.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
relapsed or refractory advanced solid tumor ... Measurable/evaluable disease or documented relapse ... per Response evaluation criteria in solid tumors (RECIST) 1.1 with at least one target lesion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Cardiac function
QTc < 470 msec (Fredericia's formula); no significant and symptomatic cardiovascular disease (such as congestive heart failure NYHA class III or higher, myocardial infarction, cerebrovascular disease, unstable angina, unstable arrhythmia) within 3 months prior to first dose
QTc ≥ 470 msec using Fredericia's formula [excluded]. Significant and symptomatic cardiovascular disease ... within the 3 months prior to first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Ohio State University · Columbus, Ohio
- START Mountain Region · West Valley City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify